Literature DB >> 23974278

Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.

Umran Kucukgoz Gulec1, Derya Gumurdulu, Ahmet Baris Guzel, Semra Paydas, Gulsah Seydaoglu, Arbil Acikalin, Ghanim Khatib, Handan Zeren, Mehmet Ali Vardar, Aytekin Altintas.   

Abstract

PURPOSE: Stage, tumor grade and histological subtype determine the clinical behavior in ovarian tumors. Some additional factors are related to tumor cell biology and are the useful predictors for identifying the patients with poor prognosis. The aim of this study is to evaluate the prognostic significance of survivin, Ki-67 and Topoisomerase IIα (TOPO IIα) in epithelial ovarian cancer (EOC).
MATERIALS AND METHODS: Seventy-three patients with EOC were included in this study. Survivin, Ki-67 and TOPO IIα expressions were studied by immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections. Nuclear staining for all antibodies was scored on a three-tiered system and more than 10 % staining was accepted as expression. The relationship between the expressions of survivin, Ki-67, TOPO IIα and clinicopathological parameters including age, stage, grade, platinum resistance and survival was evaluated.
RESULTS: Survivin, Ki-67 and TOPO IIα expressions were found in 20, 82 and 86 % of the tumors, respectively. Ki-67 and TOPO IIα expressions were found to be related to poor overall survival (p = 0.005, 0.004, respectively), while survivin expression was not associated with overall survival. There was no association between TOPO IIα and Ki-67 expressions and histological subtype, stage or grade. However, we found an important relationship between TOPO IIα expression and platinum resistance (p = 0.044). Platinum resistance was found to be an independent prognostic factor in EOC.
CONCLUSION: Ki-67 and TOPO IIα expressions were found to be related to poor overall survival, and TOPO IIα expression was found to be associated with platinum resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974278     DOI: 10.1007/s00404-013-3000-z

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Estrogen Receptors alpha and beta in Ovarian Cancer: Expression Level and Prognosis.

Authors:  T A Bogush; A A Basharina; E A Bogush; O M Ryabinina; A S Tjulandina; S A Tjulandin
Journal:  Dokl Biochem Biophys       Date:  2018-11-05       Impact factor: 0.788

2.  A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Authors:  Cheryl A Sherman-Baust; Elisabetta Kuhn; Blanca L Valle; Ie-Ming Shih; Robert J Kurman; Tian-Li Wang; Tomokazu Amano; Minoru S H Ko; Ichiro Miyoshi; Yoshihiko Araki; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Patrice J Morin
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

3.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

4.  Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Authors:  Mehmet Kanter; Gulay Turan; Ceyda Usta; Akin Usta; H Hasan Esen; Lema Tavlı; Cetin Celik; Yusuf Demirkol; Betül Kanter
Journal:  J Mol Histol       Date:  2016-01-27       Impact factor: 2.611

5.  Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Authors:  Leda Severi; Lorena Losi; Sergio Fonda; Laura Taddia; Gaia Gozzi; Gaetano Marverti; Fulvio Magni; Clizia Chinello; Martina Stella; Jalid Sheouli; Elena I Braicu; Filippo Genovese; Angela Lauriola; Chiara Marraccini; Alessandra Gualandi; Domenico D'Arca; Stefania Ferrari; Maria P Costi
Journal:  Front Pharmacol       Date:  2018-05-08       Impact factor: 5.810

6.  Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation.

Authors:  Yuzi Zhao; Jie Pi; Lihua Liu; Wenjie Yan; Shufang Ma; Li Hong
Journal:  Cancer Manag Res       Date:  2021-01-26       Impact factor: 3.989

7.  Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Qingyi Wang; Xiaoling Feng; Xiaofang Liu; Siyu Zhu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

8.  MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.

Authors:  Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.